DR55.2 DataRelease
Release Date: May 2025
New Studies: 10
Updated Studies: 7
New Studies
| SDY2281: JAX CCHI-Modulation of Lung Responses to Viral Infection – Microbiome | ||||||||||
| Status: | New | |||||||||
| Description: | 3 experiments are available: 1) whole genome sequencing of microbiome from a lung cancer cohort tongue and nasal swabs 2) metagenomic whole genome shotgun sequencing (mWGS) of the 9 donors from the lung cancer cohort (tongue and nasal swabs) and 1 lung donor from NDRI. Oral and nares samples from the participants were cultured to identify the microbial isolates. 3) bulkRNA sequencing from human derived tracheal/bronchial epithelial cells cultured in Airway Liquid Interface (commercially available from Mattek) to generate a transcriptional profile after exposure to diverse microbial isolates. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3DHN166NI | |||||||||
| Subjects: | 49 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY2903: High-throughput single-cell profiling of B cell responses following inactivated influenza vaccination in young and older adults | |||||||
| Status: | New | ||||||
| Description: | Seasonal influenza contributes to a substantial disease burden, resulting in approximately 10 million hospital visits and 50 thousand deaths in a typical year in the United States. 70 - 85% of the mortality occurs in people over the age of 65. Influenza vaccination is the best protection against the virus, but it is less effective for the elderly, which may be in part due to differences in the quantity or type of B cells induced by vaccination. To investigate this possibility, we sorted pre- and post-vaccination peripheral blood B cells from three young and three older adults with strong antibody responses to the inactivated influenza vaccine and employed single-cell technology to simultaneously profile the gene expression and the B cell receptor (BCR) of the B cells. Prior to vaccination, we observed a higher somatic hypermutation frequency and a higher abundance of activated B cells in older adults than in young adults. Following vaccination, young adults mounted a more clonal response than older adults. The expanded clones included a mix of plasmablasts, activated B cells, and resting memory B cells in both age groups, with a decreased proportion of plasmablasts in older adults. Differential abundance analysis identified additional vaccine-responsive cells that were not part of expanded clones, especially in older adults. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3GUD62MN9 | ||||||
| Subjects: | 6 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY2977: Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction | |||||||
| Status: | New | ||||||
| Description: | Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), a leading cause of death by an infectious disease globally, has no efficacious vaccine. Antibodies are implicated in Mtb control, but the mechanisms of action remain poorly understood. We assembled a library of monoclonal antibodies (mAb) and screened for Mtb-restrictive activity in mice, identifying protective antibodies targeting diverse antigens. To dissect the mechanism of mAb-mediated Mtb restriction, we optimized a protective lipoarabinomannan-specific mAb generating Fc-variants. In vivo analysis of these Fc-variants revealed a role for Fc-effector function in Mtb restriction. Restrictive Fc-variants altered distribution of Mtb across innate immune cells. Single-cell transcriptomics highlighted distinctly activated pathways within innate immune cell subpopulations, highlighting early activation of neutrophils as a key signature of mAb-mediated Mtb restriction. Therefore, antibody-mediated restriction of Mtb is associated with reorganization of the tissue-level immune response to infection and depends on the collaboration of antibody Fab and Fc. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3W8C3VAKQ | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3060: Enhancing NA immunogenicity through novel VLP designs. | |||||||||
| Status: | New | ||||||||
| Description: | Here, the investigators aimed at enhancing the immunogenicity of the NA on vaccines by two strategies: (i) modifying the HA:NA ratio of the vaccine preparation and (ii) exposing epitopes on the lateral surface or beneath the head of the NA by extending the NA stalk. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3TVD7CEA3 | ||||||||
| Subjects: | 60 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| SDY3062: Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages | |||||||
| Status: | New | ||||||
| Description: | The authors investigated the mutations in the recently dominant SARS-CoV-2 Omicron JN.1 variant by examining their individual and combined effects on immune evasion, ACE2 receptor affinity, and in vitro infectivity. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3X40Q5S0O | ||||||
| Subjects: | 43 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY3073: The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex | ||||||||||
| Status: | New | |||||||||
| Description: | The investigators evaluate the antibody response of human samples from the Stop Flu NYU cohort towards the antigenic sites of the H1 HA of the A/Michigan/45/2015 strain. They also explore whether demographic factors, such as age or sex, could influence the immunodominance of the antigenic sites exhibited by each study participant. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3Q8IT8WVC | |||||||||
| Subjects: | 39 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| SDY3076: Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity | |||||||
| Status: | New | ||||||
| Description: | The investigators designed a virus-like particle (VLP)-based vaccine presenting multiple copies of the influenza hemagglutinin (HA) from A/Puerto Rico and examined its immunogenicity and protective efficacy in ferrets. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3CUIPUNS7 | ||||||
| Subjects: | 21 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY3077: Mutability and hypermutation antagonize immunoglobulin codon optimality | |||||||
| Status: | New | ||||||
| Description: | The authors analyze germline immunoglobulin genes, natural V(D)J repertoires, serum IgG and monoclonal antibody (mAb) expression through the lens of codon optimality. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M32KYWVYGO | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY3079: COBRA N2 NA/NB vaccines and immune response | |||||||
| Status: | New | ||||||
| Description: | A recombinant COBRA N2 NA vaccine was used to elicit immune response in mice following an influenza challenge of SW/NC/15 and Kan/17. Hemagglutination-Inhibition (HAI) and influenza viral plaque assays were conducted using the mice sera samples to detect an increased antibody response that would prove more effective than current seasonal vaccines. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3BXRFFJK0 | ||||||
| Subjects: | 213 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY3081: Sleepiness is associated with antibody response to influenza vaccination | |||||||
| Status: | New | ||||||
| Description: | Analysis of sleep health as a crucial modulator of immune response to vaccines. The sleep characteristics were assessed in 210 older participants, 65 years or more of age, vaccinated with either HDFlu or MF59Flu. The specific antibody response to influenza A/H3N2 virus were measured in serum by HAI assay on the day of immunization and 28 days thereafter. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3U2F0HWAL | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
Updated Studies
| SDY2760: Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination | |||||||||||
| Status: | Updated | ||||||||||
| Description: | The researchers investigated whether particular non-neutralizing antibodies could contribute to protection from SARS-CoV-2 infection in a lethal animal model. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3RVR85FZ3 | ||||||||||
| Subjects: | 469 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY2762: XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2, HV.1, JN.1 and SARS-CoV-1, but limited XBB.1.5 specific antibodies | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Here, the investigators assessed sera collected before, 1-month and 3-months following administration of an updated XBB.1.5 monovalent vaccine to individuals with diverse infection and vaccination histories. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3HZI08OZI | ||||||||||||
| Subjects: | 25 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY2810: Sialylated IgG-induced RE1-Silencing Transcription Factor (REST) protects against lung inflammation and severe influenza disease | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | The investigators, first, profiled Fc glycans on anti-hemagglutinin (HA) IgGs from people with mild or severe influenza virus infections. Then, using a murine challenge model, they show that enrichment for sialylated, but not asialylated IgG, is broadly protective against heterologous influenza viruses. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M38BQ3HJWL | ||||||||||||
| Subjects: | 179 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: |
|
||||||||||||
| SDY2830: Antibody Responses to HA and NA vaccines | |||||||||
| Status: | Updated | ||||||||
| Description: | The study was conducted using a mouse model to assess the antibody response to COBRA vaccines combined with different adjuvants. The vaccines tested were HA-based H1 COBRA, Y2, and an NA-based N1 COBRA, N1-I and adjuvants were AddaVax, AddaS03, CpG, and Alhydrogel. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3HA37XHVE | ||||||||
| Subjects: | 210 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY2855: Vinyl Sulfone ACE-Dextran MP | |||||||||||
| Status: | Updated | ||||||||||
| Description: | Vinyl Sulfone MP expressing COBRA elicits broadly reactive antibodies | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3BTBYSD3X | ||||||||||
| Subjects: | 60 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY2918: A surrogate ELISA to select high titer human convalescent plasma for treating immunocompromised patients infected with SARS-CoV-2 variants of concern | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Here, the authors review a surrogate ELISA to select COVID-19 convalescent plasma samples that will guarantee a protective level of neutralizing antibodies as the main correlate of protection. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M36AY0IIO6 | ||||||||||||
| Subjects: | 625 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: |
|
||||||||||||
| SDY3059: Prediction of risk for early or very early preterm births using high-resolution urinary metabolomic profiling | |||||||
| Status: | Updated | ||||||
| Description: | Preterm birth (PTB) is a serious health problem. PTB complications is the main cause of death in infants under five years of age worldwide. The ability to accurately predict risk for PTB during early pregnancy would allow early monitoring and interventions to provide personalized care, and hence improve outcomes for the mother and infant. Objective: This study aims to predict the risks of early preterm (< 35 weeks of gestation) or very early preterm (≤ 26 weeks of gestation) deliveries by using high-resolution maternal urinary metabolomic profiling in early pregnancy. Design: A retrospective cohort study was conducted by two independent preterm and term cohorts using high-density weekly urine sampling. Maternal urine was collected serially at gestational weeks 8 to 24. Global metabolomics approaches were used to profile urine samples with high-resolution mass spectrometry. The significant features associated with preterm outcomes were selected by Gini Importance. Metabolite biomarker identification was performed by liquid chromatography tandem mass spectrometry (LCMS-MS). XGBoost models were developed to predict early or very early preterm delivery risk. Setting and participants: The urine samples included 329 samples from 30 subjects at Stanford University, CA for model development, and 156 samples from 24 subjects at the University of Alabama, Birmingham, AL for validation. Results: 12 metabolites associated with PTB were selected and identified for modelling among 7,913 metabolic features in serial-collected urine samples of pregnant women. The model to predict early PTB was developed using a set of 12 metabolites that resulted in the area under the receiver operating characteristic (AUROCs) of 0.995 (95% CI: [0.992, 0.995]) and 0.964 (95% CI: [0.937, 0.964]), and sensitivities of 100% and 97.4% during development and validation testing, respectively. Using the same metabolites, the very early PTB prediction model achieved AUROCs of 0.950 (95% CI: [0.878, 0.950]) and 0.830 (95% CI: [0.687, 0.826]), and sensitivities of 95.0% and 60.0% during development and validation, respectively. Conclusion: Models for predicting risk of early or very early preterm deliveries were developed and tested using metabolic profiling during the 1st and 2nd trimesters of pregnancy. With patient validation studies, risk prediction models may be used to identify at-risk pregnancies prompting alterations in clinical care, and to gain biological insights of preterm birth. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3BDM7MFH4 | ||||||
| Subjects: | 54 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||